Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 2/2013

01-04-2013 | Nephrology – Original Paper

Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients

Authors: Mehmet Tanrisev, Gulay Asci, Ozkan Gungor, Fatih Kircelli, Ebru Sevinc Ok, Mumtaz Yilmaz, Osman Z. Sahin, Kezban Pinar Ozen, Gultekin Suleymanlar, Huseyin Toz, Ercan Ok

Published in: International Urology and Nephrology | Issue 2/2013

Login to get access

Abstract

Background

Recently, low serum estradiol levels have been associated with increased cardiovascular risk and mortality in non-uremic patient populations. We investigated the predictive value of serum estradiol levels for mortality in female hemodialysis patients.

Methods

One hundred and forty-seven prevalent female hemodialysis patients were included in March 2005 and followed up for 32 ± 16 months. Serum estradiol levels were determined by ELISA at baseline and studied in relation to cardiovascular and overall mortality.

Results

Mean serum estradiol level was 28.6 ± 15.4 pg/ml (5.7–81.3). Patients in the higher estradiol tertile were likely to be more often diabetic and to have more cardiovascular diseases and higher body mass index (BMI). Serum estradiol was inversely correlated with age and urea reduction rate and positively correlated with postdialysis body weight, BMI and hs-CRP levels. During the follow-up period, 52 (35.6 %) patients died. Patients who died were older, had shorter dialysis vintage, were more likely to have a history of diabetes and cardiovascular disease, and lower serum creatinine, albumin, hemoglobin, and higher hs-CRP levels than those who survived. In Cox regression analysis, estradiol levels, in a bimodal (U-shaped) distribution, along with diabetes, low serum albumin and high hs-CRP levels, were predictors for overall mortality.

Conclusions

A U-shaped association between serum estradiol levels and cardiovascular and overall mortality was found in postmenopausal hemodialysis patients.
Literature
1.
Tauchmanovà L, Carrano R, Sabbatini M et al (2004) Hypothalamic-pituitary-gonadal axis function after successful kidney transplantation in men and women. Hum Reprod 19:867–873PubMedCrossRef
2.
Bellinghieri G, Santoro D, Mallamace A, Savica V (2008) Sexual dysfunction in chronic renal failure. J Nephrol 13:113–117
3.
Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048–1056PubMedCrossRef
4.
Shabsigh R, Katz M, Yan G, Makhsida N (2005) Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 96:67–72CrossRef
5.
Carrero JJ, Qureshi AR, Parini P et al (2009) Low serum testosterone increase mortality risk among male dialysis patients. J Am Soc Nephrol 20:613–620PubMedCrossRef
6.
Gungor O, Kircelli F, Carrero JJ et al (2010) Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin J Am Soc Nephrol 5:2018–2023PubMedCrossRef
7.
Gorton T (1964) Blood pressure of adults by age and sex: United States 1960–1962. Vital Health Stat 11:1–40
8.
Ginsburg ES, Walsh B, Greenberg L, Price D, Chertow GM, Owen WF Jr (1998) Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney Int 54:1344–1350PubMedCrossRef
9.
Seely EW, Walsh BW, Gerhard MD, Williams GH (1999) Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 335:1190–1194CrossRef
10.
11.
Rexrode KM, Manson JE, Lee IM et al (2003) Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 108:1688–1693PubMedCrossRef
12.
Stampfer MJ, Colditz GA, Willett WC et al (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 325:756–762PubMedCrossRef
13.
Wilson PWF, Garrison RJ, Castelli WP (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 313:1038–1043PubMedCrossRef
14.
Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH (1985) A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 313:1044–1049PubMedCrossRef
15.
Song YS, Yang HJ, Song ES, Han DC, Moon C, Ku JH (2008) Sexual function and quality of life in Korean women with chronic renal failure on hemodialysis: case-control study. Urology 71:243–246PubMedCrossRef
16.
Sugiya N, Nakashima A, Takasugi N et al (2011) Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life. Osteoporos Int 22:1573–1579PubMedCrossRef
17.
Kramer HM, Curhan G, Singh A, HELP Study Group (2003) Hemodialysis and estrogen levels in postmenopausal (HELP) patients: the multicenter HELP study. Am J Kidney Dis 41:1240–1246PubMedCrossRef
18.
19.
Nakamura S, Yoshimura M, Nakayama M et al (2004) Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation 110:1787–1793PubMedCrossRef
20.
Patten RD, Pourati I, Aronovitz MJ et al (2004) 17 beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 95:692–699PubMedCrossRef
21.
Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS (2000) Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 97:12729–12734PubMedCrossRef
22.
Ohlsson C, Hellberg N, Parini P et al (2000) Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun 278:640–645PubMedCrossRef
23.
Barrett-Connor E, Khaw KT (1988) Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation 78:539–545PubMedCrossRef
24.
Fukai S, Akishita M, Yamada S et al (2011) Plasma sex hormone levels and mortality in disabled older men and women. Geriatr Gerontol Int 112:196–203CrossRef
25.
Saltiki K, Papageorgiou G, Voidonikola P et al (2010) Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels. Endocrine 37:329–335PubMedCrossRef
26.
Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE (2004) Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 19:791–804PubMedCrossRef
27.
Jankowska EA, Rozentryt P, Ponikowska B et al (2009) Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA 301:1892–1901PubMedCrossRef
28.
Karas RH, Hodgin JB, Kwoun M et al (1999) Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci USA 96:15133–15136PubMedCrossRef
29.
Cushman M, Legault C, Barrett-Connor E et al (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 100:717–722PubMedCrossRef
30.
Nakagami F, Nakagami H, Osako MK et al (2010) Estrogen attenuates vascular remodeling in Lp(a) transgenic mice. Atherosclerosis 211:41–47PubMedCrossRef
31.
Karpuzoglu E, Ahmed SA (2006) Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide 15:177–186PubMedCrossRef
32.
Krolner B (1979) Serum levels of testosterone and luteinizing hormone in patients with chronic renal disease. Acta Med Scand 205:623–627PubMedCrossRef
33.
Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P (2010) The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 19:37–42PubMedCrossRef
34.
Ricks J, Molnar MZ, Kovesdy CP et al (2011) Racial and ethnic differences in the association of body mass index and survival in maintenance hemodialysis patients. Am J Kidney Dis 58:574–582PubMedCrossRef
35.
Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288–1299PubMedCrossRef
36.
Goodman-Gruen D, Barrett-Connor E (2000) Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 23:912–918PubMedCrossRef
37.
Golden SH, Dobs AS, Vaidya D et al (2007) Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 92:1289–1295PubMedCrossRef
38.
Maggio M, Ceda GP, Lauretani F et al (2009) Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. J Am Geriatr Soc 57:1810–1815PubMedCrossRef
39.
Barros RP, Machado UF, Warner M, Gustafsson JA (2006) Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci USA 31:1605–1608CrossRef
Metadata
Title
Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients
Authors
Mehmet Tanrisev
Gulay Asci
Ozkan Gungor
Fatih Kircelli
Ebru Sevinc Ok
Mumtaz Yilmaz
Osman Z. Sahin
Kezban Pinar Ozen
Gultekin Suleymanlar
Huseyin Toz
Ercan Ok
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0171-7

Other articles of this Issue 2/2013

International Urology and Nephrology 2/2013 Go to the issue

Nephrology - Original Paper

Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy

Urology - Original Paper

Induction of cold ischemia in patients with solitary kidney using retrograde intrarenal cooling: 2-year functional outcomes

Nephrology - Original Paper

Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery

Nephrology - Original Paper

Long-term effects of peritonitis on peritoneal dialysis outcomes

Nephrology - Original Paper

The effects of mammalian target of rapamycin inhibitors on serum uric acid levels in renal transplant patients

Nephrology - Original Paper

Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition–inflammation–atherosclerosis syndrome in patients with chronic kidney disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits